Atea Pharmaceuticals Q1 net loss widens on higher R&D spending

Atea Pharmaceuticals

12/05/2026 21:27

Overview

U.S. antiviral drug developer's Q1 net loss widened on higher R&D spending for HCV and HEV programs

Company ended Q1 with $256 mln in cash, down from $302 mln at year-end

Phase 3 HCV trials and preclinical HEV candidate remain on track for key 2026 milestones

Outlook

Topline results from North American Phase 3 HCV trial expected mid-2026

International Phase 3 HCV trial enrollment to complete mid-2026; topline results expected around year-end 2026

Phase 1 clinical program for HEV candidate AT-587 expected to begin mid-2026

Result Drivers

HIGHER R&D SPENDING - Increased research and development expenses driven by Phase 3 HCV clinical development and HEV preclinical work

LOWER G&A COSTS - General and administrative expenses declined due to lower salaries, stock-based compensation and professional fees

Company press release: ID:nGNXbHmkkn

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.57
Q1 Operating Expenses
$48.008 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $10.00, about 84.8% above its May 11 closing price of $5.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)